Valvular heart disease nursing: a complete reference guide

LS
By Lindsay Smith, AGPCNP
Updated May 27, 2026

Reviewed for clinical accuracy · Methodology: NIH, NCBI, AANP guidelines

Introduction

Valvular heart disease (VHD) encompasses any disorder affecting the structure or function of the heart’s four valves – mitral, aortic, tricuspid, and pulmonic. Each valve can develop stenosis (restricted opening, impeding forward flow) or regurgitation (incomplete closure, allowing backward flow). The nursing implications differ sharply between valve types, between stenosis and regurgitation, and between acute and chronic presentations.

This reference covers the six major valvular disorders tested on NCLEX and encountered in medical-surgical and critical care settings: mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation, tricuspid regurgitation, and pulmonic stenosis. For each, you will find pathophysiology, clinical presentation, murmur characteristics, and nursing priorities – plus three reference tables and 12 NCLEX tips that tie the concepts together.

Valvular disease quick reference

Valve/type Etiology Murmur Key exam finding Treatment
Mitral stenosis Rheumatic heart disease (#1); congenital; mitral annular calcification Low-pitched diastolic rumble at apex; opening snap preceding murmur LA enlargement; AFib; pulmonary congestion; malar flush Rate control; anticoagulation for AFib; balloon valvuloplasty; MVR
Mitral regurgitation Acute: papillary muscle rupture post-MI, endocarditis, chordae rupture. Chronic: MVP, rheumatic disease, LA/LV dilation Holosystolic (pansystolic) blowing murmur at apex, radiates to axilla LA and LV dilation; S3 gallop; pulmonary edema in acute MR Afterload reduction (ACE inhibitor/nitroprusside); surgical repair or replacement
Aortic stenosis Calcific/degenerative (elderly, #1 in US); bicuspid aortic valve; rheumatic disease Harsh crescendo-decrescendo systolic ejection murmur at right upper sternal border; radiates to carotids Classic triad: syncope, angina, dyspnea on exertion; pulsus parvus et tardus; diminished S2 TAVR (transcatheter); surgical AVR; no effective medical therapy for severe AS
Aortic regurgitation Acute: aortic dissection, infective endocarditis. Chronic: bicuspid AV, Marfan syndrome, syphilis, rheumatic High-pitched early diastolic blowing murmur at left sternal border; Austin Flint murmur (diastolic rumble at apex) Bounding pulses (Corrigan's/water-hammer); wide pulse pressure; head bobbing (de Musset's sign) Acute: emergent surgical AVR. Chronic: vasodilators (ACE inhibitor/nifedipine); surgical AVR when symptomatic or EF declining
Tricuspid regurgitation Secondary to RV dilation/failure (#1); infective endocarditis (IV drug use); rheumatic disease; carcinoid Holosystolic murmur at left lower sternal border; increases with inspiration (Carvallo's sign) JVD with prominent CV waves; hepatomegaly; peripheral edema; pulsatile liver Treat underlying RV failure; surgical repair or replacement for severe primary TR; diuretics
Pulmonic stenosis Usually congenital (tetralogy of Fallot, rubella); rarely acquired Systolic ejection murmur at left upper sternal border; ejection click; widely split S2 Right ventricular hypertrophy; parasternal heave; prominent jugular A wave Balloon valvuloplasty for moderate-severe PS; surgical valvotomy; generally good prognosis

Murmur characteristics comparison

Murmur Timing Best heard Radiation Quality/pitch Additional sounds
Mitral stenosis Diastolic (mid to late); rumble Apex; left lateral decubitus position Minimal; localized to apex Low-pitched rumble (bell of stethoscope) Opening snap (OS) after S2; earlier OS = more severe stenosis
Mitral regurgitation Holosystolic (pan-systolic); throughout systole from S1 to S2 Apex To the left axilla; sometimes to the back High-pitched blowing S3 gallop in volume overload; soft S1
Aortic stenosis Systolic ejection; crescendo-decrescendo (diamond-shaped) Right upper sternal border (2nd intercostal space, RSB) To carotid arteries bilaterally Harsh, coarse, rasping Diminished/absent S2; ejection click in bicuspid AV; narrow pulse pressure
Aortic regurgitation Early diastolic; decrescendo (fades as pressures equalize) Left sternal border (3rd–4th ICS); patient sitting up, leaning forward, breath held in expiration Down left sternal border toward apex High-pitched blowing Austin Flint murmur (diastolic rumble at apex); wide pulse pressure; S3
Tricuspid regurgitation Holosystolic Left lower sternal border (4th–5th ICS) Minimal Soft, blowing Carvallo's sign: murmur increases with inspiration (more venous return to right heart)
Pulmonic stenosis Systolic ejection; crescendo-decrescendo Left upper sternal border (2nd ICS) Minimal; sometimes toward the left clavicle Harsh; preceded by ejection click Widely split S2 (delayed pulmonic component); RV heave

Mitral stenosis

Pathophysiology

The mitral valve separates the left atrium (LA) from the left ventricle (LV). In mitral stenosis (MS), fusion and fibrosis of the valve leaflets – most commonly from rheumatic heart disease – progressively narrow the mitral valve orifice. Normal mitral valve area (MVA) is 4–6 cm²; symptoms typically emerge when MVA falls below 2.0 cm², and stenosis is considered severe at MVA less than 1.5 cm².

As the valve narrows, blood backs up behind the obstruction. Left atrial pressure rises chronically, causing LA enlargement – the hallmark structural consequence of mitral stenosis. Elevated LA pressure transmits backward to the pulmonary veins and pulmonary capillaries, eventually producing pulmonary hypertension, right heart failure, and pulmonary edema.

The LA dilation is the substrate for atrial fibrillation. AFib develops in up to 40% of patients with significant mitral stenosis and is a pivotal complication: the loss of atrial kick (atrial contraction contributing to ventricular filling) further reduces cardiac output across the already narrowed valve, and the slow, irregular rhythm allows more time for thrombus formation in the enlarged, hypocontractile LA appendage. Systemic embolism and stroke are major risks. See the atrial fibrillation nursing reference for anticoagulation management.

Etiology

  • Rheumatic heart disease – the dominant cause worldwide. Group A Streptococcal pharyngitis triggers an autoimmune inflammatory response (rheumatic fever) that damages valve leaflets, causing leaflet fusion, calcification, and subvalvular scarring. The mitral valve is most commonly affected. Symptoms of MS typically appear 20–40 years after the initial rheumatic fever episode.
  • Mitral annular calcification – degenerative calcification of the mitral annulus in elderly patients; less severe than rheumatic MS
  • Congenital – rare; may present in infancy or childhood

Clinical presentation

  • Dyspnea on exertion progressing to dyspnea at rest – the most common symptom; from pulmonary venous hypertension and pulmonary edema
  • Orthopnea and paroxysmal nocturnal dyspnea – position-dependent worsening of pulmonary congestion
  • Fatigue – reduced cardiac output from the fixed obstruction at the mitral valve
  • Palpitations – AFib, which worsens symptoms acutely
  • Hemoptysis – rupture of dilated bronchial vessels under chronically elevated pulmonary venous pressure; typically blood-streaked sputum
  • Malar flush (mitral facies) – a rosy or ruddy discoloration of the cheeks in patients with chronic low cardiac output and pulmonary hypertension; more common in young patients; rarely seen today
  • Right heart failure signs – JVD, peripheral edema, hepatomegaly – in advanced disease with pulmonary hypertension
  • Opening snap – a crisp, high-pitched early diastolic sound caused by the sudden tensing of the fused mitral leaflets when they reach maximum opening; heard best at the apex. The interval between S2 and the opening snap shortens as stenosis worsens (higher LA pressure = earlier valve opening).
  • Diastolic rumble – the low-pitched mid-diastolic murmur of blood turbulently crossing the narrowed valve; heard best at the apex with the patient in left lateral decubitus position, using the bell of the stethoscope

Management

Medical:

  • Rate control – slowing the heart rate allows more diastolic filling time across the stenotic valve; beta-blockers or rate-limiting calcium channel blockers (diltiazem, verapamil); critical in patients with AFib
  • Anticoagulation – all patients with MS and AFib require anticoagulation (warfarin preferred; NOACs are used but evidence is less established for MS-related AFib); goal is to prevent LA thrombus and stroke
  • Diuretics – reduce pulmonary congestion; loop diuretics (furosemide) for symptom relief; use cautiously to avoid excess preload reduction
  • Antibiotic prophylaxis for recurrent Streptococcal infection (rheumatic fever prevention) in patients with a history of rheumatic fever

Interventional:

  • Percutaneous mitral balloon valvuloplasty (PMBV) – the procedure of choice for suitable anatomy (pliable, non-calcified leaflets, no LA thrombus, no more than mild mitral regurgitation). A balloon catheter is advanced across the mitral valve and inflated, splitting the fused commissures. Highly effective and durable in appropriate patients.
  • Surgical mitral valve repair or replacement (MVR) – for patients with unfavorable valve anatomy, significant calcification, or concomitant mitral regurgitation; tissue or mechanical prostheses (mechanical requires lifelong anticoagulation)

Mitral regurgitation

Pathophysiology

In mitral regurgitation (MR), the mitral valve fails to close completely during systole, allowing blood to flow backward from the LV into the LA. This volume overload creates two distinct syndromes depending on onset: acute MR and chronic MR are hemodynamically and clinically very different.

Acute MR is a cardiac emergency. The LA has not had time to dilate and accommodate the sudden volume overload – LA pressure spikes dramatically, transmitting immediately to the pulmonary vasculature. The result is flash pulmonary edema and cardiogenic shock. Patients are critically ill within hours.

Chronic MR develops gradually over months to years. The LA and LV dilate progressively to accommodate the regurgitant volume, maintaining forward cardiac output at the cost of chamber enlargement. For years, patients may be asymptomatic. Eventually, LV dysfunction develops – the chronically volume-overloaded ventricle dilates beyond its ability to compensate, and ejection fraction falls. Once symptomatic or EF declines below 60%, surgical intervention becomes urgent.

Etiology

Acute:

  • Papillary muscle rupture – a catastrophic complication of myocardial infarction, typically occurring 2–7 days post-MI (the posterior papillary muscle is more commonly affected because it has a single blood supply from the RCA). Sudden, severe MR causes hemodynamic collapse. See the MI/ACS nursing reference for the ACS context.
  • Chordae tendineae rupture – from endocarditis, myxomatous degeneration, or trauma
  • Infective endocarditis – vegetation disrupts leaflet coaptation; see infective endocarditis nursing

Chronic:

  • Mitral valve prolapse (MVP) – the most common cause of chronic primary MR in developed countries; myxomatous degeneration of leaflets allows posterior leaflet billowing into the LA during systole
  • Rheumatic heart disease – leaflet retraction and fibrosis prevents closure; usually mixed stenosis and regurgitation
  • Dilated cardiomyopathy – annular dilation from LV enlargement causes functional (secondary) MR without intrinsic leaflet disease; see cardiomyopathy nursing
  • Ischemic MR – regional wall motion abnormalities from coronary disease distort papillary muscle geometry chronically

Clinical presentation

Acute MR:

  • Abrupt onset dyspnea, orthopnea, pulmonary edema
  • Cardiogenic shock – hypotension, tachycardia, cold/clammy skin, decreased urine output
  • New harsh holosystolic murmur at apex (may be soft if cardiac output is severely reduced)
  • CXR: pulmonary edema without cardiomegaly (no time for cardiac enlargement)

Chronic MR:

  • Exertional dyspnea, fatigue – develop insidiously over years
  • Holosystolic blowing murmur at the apex, radiating to the left axilla; high-pitched; present throughout systole from S1 to S2
  • S3 gallop – from volume overload and LV dilation
  • Displaced PMI – LV enlargement shifts the apical impulse laterally
  • LA enlargement – risks AFib and thrombus formation
  • Signs of left heart failure in decompensated chronic MR

Management

Acute MR:

  • IV vasodilators – sodium nitroprusside reduces afterload, decreasing the fraction of stroke volume that regurgitates backward and improving forward output. This is the pharmacologic bridge to surgery.
  • Intra-aortic balloon pump (IABP) – reduces afterload mechanically; used as bridge to surgery when nitroprusside is insufficient
  • Emergent surgical repair or replacement – definitive treatment; acute severe MR carries very high mortality without urgent surgery
  • Avoid beta-blockers – slowing the heart rate in acute MR increases regurgitant volume per beat

Chronic MR:

  • ACE inhibitors – reduce afterload in symptomatic patients; preserve LV function; standard management in LV dysfunction
  • Loop diuretics – manage volume overload and pulmonary congestion
  • Surgical mitral valve repair (preferred) or replacement – indicated when symptoms develop, when EF falls below 60%, or when LV end-systolic diameter exceeds 40 mm
  • Transcatheter edge-to-edge repair (MitraClip) – for high surgical-risk patients with secondary MR and heart failure; improves symptoms and reduces HF hospitalizations

Aortic stenosis

Pathophysiology

Aortic stenosis (AS) is the most common valvular heart disease requiring intervention in developed countries. The aortic valve separates the LV from the aorta; when stenotic, it obstructs LV outflow during systole. The LV responds with compensatory concentric hypertrophy – the walls thicken to maintain stroke volume against the increased pressure gradient. For years, the hypertrophied LV sustains near-normal cardiac output. Eventually, the ventricle fails to compensate: symptoms emerge, and median survival without intervention drops sharply.

Severe AS is defined as aortic valve area (AVA) less than 1.0 cm² (normal: 3–4 cm²) or a mean gradient greater than 40 mmHg. The valve gradient drives turbulent flow through the narrowed orifice, generating the characteristic harsh ejection murmur.

Etiology

  • Calcific (degenerative) aortic stenosis – the most common cause in adults over 65 in the United States. Progressive calcium deposits accumulate on leaflet bases over decades. Age, male sex, hypertension, hyperlipidemia, and smoking accelerate calcification. This is fundamentally an active inflammatory process resembling atherosclerosis.
  • Bicuspid aortic valve (BAV) – a congenital abnormality affecting 1–2% of the population; the valve has two leaflets instead of three. Abnormal leaflet architecture causes turbulent flow and accelerated calcification; AS typically presents 20–30 years earlier than in tricuspid valves (often in patients in their 50s–60s). BAV is also associated with aortic root dilation and aortic dissection risk.
  • Rheumatic AS – commissural fusion from prior rheumatic fever; less common in developed countries

Clinical presentation: the classic triad

The three hallmark symptoms of severe aortic stenosis represent sequential stages of decompensation. Their onset marks a sharp deterioration in prognosis without intervention:

  1. Angina – the first symptom to appear (average survival 5 years without intervention). The hypertrophied LV has increased oxygen demand but impaired coronary perfusion reserve – subendocardial ischemia occurs during demand states even without obstructive coronary artery disease. Nitroglycerin for AS-related angina must be used cautiously – it reduces preload and afterload, potentially causing severe hypotension in the pressure-dependent AS patient.

  2. Syncope (exertional) – average survival 3 years without intervention. During exercise, peripheral vasodilation occurs normally, but the fixed stenotic obstruction prevents the LV from increasing cardiac output proportionally. The result is a sudden fall in systemic blood pressure and cerebral perfusion. The mechanism may also involve vasodepressor reflex activation.

  3. Dyspnea (heart failure) – average survival 1–2 years without intervention. The LV ultimately fails – the hypertrophied, stiff ventricle develops diastolic dysfunction, elevated filling pressures, and pulmonary venous hypertension. Eventually systolic dysfunction supervenes.

Additional physical exam findings

  • Pulsus parvus et tardus – the carotid pulse is weak and delayed (small amplitude, slow upstroke) due to reduced stroke volume crossing the stenotic valve; best appreciated by simultaneous palpation of the carotid and cardiac apex
  • Diminished or absent S2 – calcified leaflets lose their closing snap; S2 becomes quiet, single, or paradoxically split
  • Ejection click – a high-pitched sound just after S1, present only in bicuspid AV before calcification occurs; disappears as the valve becomes immobile
  • Narrow pulse pressure – reduced stroke volume
  • Systolic thrill – palpable vibration at the right upper sternal border in severe AS

Management

Medical – limitation: There is no medication proven to delay progression of AS. Statins, which were theorized to slow progression, did not reduce events in large trials. Medical therapy addresses symptoms and co-existing conditions (hypertension, heart failure) but does not replace intervention.

Interventional:

  • Transcatheter aortic valve replacement (TAVR) – the standard of care for severe symptomatic AS in patients of any surgical risk. A bioprosthetic valve is delivered via catheter (typically transfemoral) and deployed within the native calcified valve. Originally used for high-risk patients, TAVR is now approved for intermediate and low surgical risk. Requires dual antiplatelet therapy post-procedure.
  • Surgical aortic valve replacement (SAVR) – open-heart surgery; preferred in younger, low-surgical-risk patients (particularly with BAV), those needing concomitant bypass surgery, or when anatomy is unsuitable for TAVR
  • Balloon aortic valvuloplasty – temporary dilation of the stenotic valve; used as a bridge to definitive intervention (TAVR/SAVR) in hemodynamically unstable patients; not durable as a long-term solution

See heart failure nursing for the acute decompensated HF management that may be needed before valve intervention.

Aortic regurgitation

Pathophysiology

In aortic regurgitation (AR), the aortic valve fails to close completely during diastole, allowing blood to flow back from the aorta into the LV. The regurgitant volume increases LV end-diastolic volume (volume overload), causing progressive LV dilation and eccentric hypertrophy – the LV enlarges to accommodate the combined forward and regurgitant volumes.

As in MR, the hemodynamics of acute and chronic AR differ dramatically.

Acute AR is a cardiac emergency. The LV has not had time to dilate – normal diastolic pressure is suddenly overwhelmed by the high-pressure aortic regurgitant flow. LV end-diastolic pressure rises precipitously, closes the mitral valve prematurely (premature mitral valve closure), and back-pressures into the pulmonary circulation: flash pulmonary edema and cardiogenic shock. Patients deteriorate within hours.

Chronic AR allows years of progressive LV dilation and volume adaptation, during which patients may remain asymptomatic. The dilating LV accommodates increasing regurgitant volume. The aortic root often enlarges as well. Eventually, LV dysfunction develops.

The widened pulse pressure – the difference between systolic and diastolic BP – is the hemodynamic signature of chronic AR. The regurgitant volume swells aortic systolic pressure while diastole is shortened by the backward leak, dropping diastolic pressure. A pulse pressure greater than 60 mmHg suggests significant AR.

Etiology

Acute:

  • Aortic dissection – Type A dissection can involve the aortic valve root, causing acute AR; a cardiovascular emergency. See aortic dissection nursing
  • Infective endocarditis – leaflet destruction from vegetations; see infective endocarditis nursing
  • Trauma – blunt chest trauma causing leaflet prolapse

Chronic:

  • Bicuspid aortic valve – same structural abnormality that causes AS; can also cause AR from leaflet prolapse
  • Aortic root dilation – Marfan syndrome, Ehlers-Danlos syndrome, or idiopathic aortic root enlargement; the root dilates, pulling the leaflets apart during diastole
  • Rheumatic heart disease – leaflet scarring and retraction; often mixed stenosis and regurgitation
  • Syphilitic aortitis – historical cause; inflammation of the ascending aorta and aortic root

Clinical presentation and peripheral signs

Chronic AR produces a constellation of physical signs from the bounding, high-amplitude arterial pulse:

  • Corrigan’s pulse (water-hammer pulse) – an abrupt, forceful systolic impulse that collapses rapidly; felt in the carotid or radial arteries; caused by the large stroke volume and rapid diastolic runoff
  • de Musset’s sign – head bobbing synchronous with the heartbeat; from the same mechanism
  • Quincke’s pulse – visible nail bed pulsations (capillary pulsations) visible with gentle pressure on the fingertip
  • Duroziez’s sign – a systolic and diastolic bruit heard over the femoral artery with partial compression
  • Traube’s sign – a pistol-shot sound heard over the femoral artery
  • Widened pulse pressure – systolic BP elevated; diastolic BP low (often below 60 mmHg)
  • Diastolic murmur – high-pitched early diastolic blowing murmur at the left sternal border; best heard with the diaphragm, patient sitting forward, breath held at end-expiration; decrescendo in character
  • Austin Flint murmur – a diastolic rumble at the apex mimicking mitral stenosis; caused by the regurgitant jet impinging on the anterior mitral leaflet, causing functional mitral obstruction

Management

Acute AR:

  • Emergent surgical aortic valve replacement – the only effective treatment; medical stabilization is a very short bridge
  • IV vasodilators (nitroprusside) – reduce afterload and regurgitant fraction temporarily
  • Inotropes (dobutamine) – support forward output
  • AVOID beta-blockers – slowing the heart rate in acute AR allows more time for diastolic regurgitation, worsening the hemodynamic burden

Chronic AR:

  • Vasodilators – ACE inhibitors or nifedipine in symptomatic patients or those with LV dysfunction; reduce afterload and regurgitant fraction; slow LV dilation
  • Surgical AVR – indicated when symptoms develop, when EF falls below 55%, when LV end-systolic diameter exceeds 50–55 mm, or when progressive LV dilation is documented

Tricuspid regurgitation

Pathophysiology

The tricuspid valve separates the right atrium (RA) from the right ventricle (RV). Tricuspid regurgitation (TR) allows backward flow from the RV to the RA during systole. In most cases, TR is functional (secondary) – the tricuspid valve leaflets and chordae are structurally normal, but RV pressure overload or dilation from left-sided heart disease stretches the tricuspid annulus, preventing complete leaflet coaptation.

Severe TR elevates right atrial pressure, which back-pressures into the systemic venous circulation. The classic signs of TR are all downstream consequences of chronically elevated venous pressure.

Etiology

  • Secondary to right heart failure – the most common mechanism; left-sided heart failure, pulmonary hypertension from any cause (see pulmonary hypertension nursing), dilated cardiomyopathy, or chronic left-sided valve disease all elevate right-sided pressures
  • Infective endocarditis – particularly in IV drug users; the tricuspid valve is the right-sided valve most exposed to bacteremic insults from injected material. Staphylococcus aureus is the predominant organism; septic pulmonary emboli are a key complication.
  • Rheumatic disease – rarely isolated; usually accompanies rheumatic mitral disease
  • Carcinoid syndrome – carcinoid tumor deposits fibrous plaques on right-sided heart valves, causing TR (and pulmonic stenosis); associated with elevated 5-HIAA and carcinoid flushing

Clinical presentation

All findings reflect chronically elevated systemic venous pressure:

  • Jugular venous distension (JVD) – prominent; with characteristic CV waves visible on inspection of the neck veins
  • Pulsatile liver (hepatic pulsations) – systolic pulsations of the liver from transmitted RV pressure; felt with gentle palpation of the right upper quadrant
  • Hepatomegaly – congestive hepatopathy from chronic venous congestion
  • Ascites – from portal hypertension secondary to hepatic congestion
  • Peripheral edema – bilateral, dependent; from elevated venous pressure and neurohormonal fluid retention
  • Fatigue – reduced right heart output
  • Holosystolic murmur at the left lower sternal border; characteristically increases with inspiration (Carvallo’s sign) – inspiration increases venous return to the right heart, increasing regurgitant flow across the tricuspid valve and augmenting the murmur

For a comprehensive view of right heart failure signs, see the heart failure nursing reference.

Management

  • Treat the underlying cause – correcting the causative left-sided lesion (e.g., MVR for mitral stenosis) often reduces RV pressure and secondary TR over time
  • Diuretics – loop diuretics reduce systemic venous congestion; spironolactone for persistent edema and ascites
  • Surgical repair or replacement – annuloplasty (ring repair) is preferred; replacement with a bioprosthesis for irreparable leaflet disease; typically performed at the time of left-sided valve surgery
  • Endocarditis management – long-course IV antibiotics; surgery for persistent bacteremia, recurrent septic emboli, or vegetations causing severe regurgitation

Pulmonic stenosis

Pathophysiology

Pulmonic stenosis (PS) is narrowing of the pulmonic valve or subvalvular/supravalvular region, obstructing RV outflow into the pulmonary artery. The RV responds with hypertrophy (as the LV does in AS), and with enough obstruction, eventually dilates and fails.

Unlike the other valvular diseases, pulmonic stenosis is almost always congenital. It is one of the most common congenital heart defects encountered in adult cardiology practice.

Etiology

  • Congenital – accounts for the vast majority of cases; may be isolated or part of a syndrome:
    • Tetralogy of Fallot – the most common cyanotic congenital heart disease; includes RV outflow tract obstruction, VSD, overriding aorta, RVH
    • Rubella syndrome – maternal rubella infection in the first trimester causes multiple cardiac defects including PS
    • Noonan syndrome – autosomal dominant; dysplastic pulmonary valve
  • Carcinoid – acquired; carcinoid fibrous plaques deposit on right-sided valves, causing both pulmonic stenosis and tricuspid regurgitation

Clinical presentation

Mild PS (gradient <25 mmHg) is typically asymptomatic. Moderate to severe PS produces:

  • Exertional dyspnea and fatigue – from reduced RV output
  • Exertional syncope – fixed RV outflow obstruction limits cardiac output response to exercise
  • Right-sided heart failure signs – JVD, peripheral edema, hepatomegaly, ascites in severe, longstanding PS
  • Parasternal heave – RV hypertrophy producing a palpable left parasternal lift
  • Prominent jugular A wave – forceful right atrial contraction against a hypertrophied, non-compliant RV
  • Systolic ejection murmur at the left upper sternal border; preceded by an ejection click (the click is louder with expiration in PS – opposite of aortic ejection click)
  • Widely split S2 – pulmonic valve closure is delayed by the obstruction

Management

  • Balloon pulmonary valvuloplasty – the definitive treatment for moderate to severe valvular PS (gradient >40 mmHg or symptomatic patients); outcomes are excellent; most patients do not require repeat procedures
  • Surgical valvotomy or valve replacement – for dysplastic valves unsuitable for balloon techniques, or in the context of complex congenital heart disease
  • Prognosis – isolated PS carries a favorable long-term prognosis with appropriate intervention; the valve gradient frequently remains stable or progresses slowly over decades in mild cases

Nursing priorities by valve disorder

Valve disorder Assessment priorities Key nursing interventions Medications Patient teaching priorities
Mitral stenosis Respiratory status (dyspnea, crackles, SpO2); heart rate/rhythm (AFib); LA enlargement on CXR; JVD; peripheral edema Positioning (HOB 30–45°); continuous telemetry for AFib; fluid balance monitoring; O2 as needed; fall precautions (anticoagulated) Rate-controlling agents (beta-blocker or diltiazem/verapamil); warfarin or NOAC for AFib; loop diuretics (furosemide) for congestion Anticoagulation compliance; INR monitoring schedule; signs of AFib and when to seek care; exercise limits; dental/procedure prophylaxis instructions
Mitral regurgitation (acute) Hemodynamics every 15–30 min (hypotension, tachycardia = cardiogenic shock); pulmonary edema (crackles, SpO2, respiratory rate); urine output; mental status Emergent ICU admission; IV vasodilator administration (nitroprusside) per protocol; prepare for emergent cardiac catheterization or surgery; IABP care if placed IV sodium nitroprusside (arterial line required); IV diuretics; avoid beta-blockers and any HR-slowing agents; vasopressors if shock Emergency context – focus on immediate interventions and surgical consent; support family; explain urgency of intervention
Aortic stenosis Syncope/presyncope; anginal symptoms; dyspnea (triad monitoring); BP (narrow pulse pressure); carotid pulsation quality; activity tolerance decline Fall prevention (syncope risk); caution with vasodilators (hypotension risk); activity limits; continuous telemetry; post-TAVR/SAVR care (access site, AV conduction monitoring) No disease-modifying medications. Symptom management: diuretics for HF; beta-blockers for rate control. AVOID nitrates for angina (cause hypotension). Post-TAVR: dual antiplatelet therapy (aspirin + clopidogrel) Symptom progression and when to report (especially new syncope); activity restrictions; no safe "take a nitroglycerin" – must call 911 for chest pain; TAVR/SAVR follow-up
Aortic regurgitation (chronic) Pulse pressure assessment (systolic minus diastolic); peripheral pulse character (bounding, water-hammer quality); LV size trend (serial echo); signs of LV failure (crackles, S3, dyspnea) Monitor for acute decompensation; ensure medication adherence; support activity as tolerated; educate on symptom reporting ACE inhibitors or nifedipine (vasodilation, reduce afterload); diuretics if fluid overloaded; avoid beta-blockers in acute AR; anticoagulation only if concurrent AFib Report new dyspnea, decreased exercise tolerance, chest discomfort promptly – these indicate LV decompensation and need for surgical evaluation; endocarditis prophylaxis if applicable
Tricuspid regurgitation JVD assessment; peripheral edema measurement; abdominal girth and RUQ tenderness (hepatomegaly); daily weights; I&O; hepatic function labs (elevated bilirubin, transaminases in congestive hepatopathy) Elevate lower extremities; strict I&O and daily weights; sodium restriction; skin care for edematous extremities; IV drug use harm reduction and endocarditis prevention education Loop diuretics (furosemide); aldosterone antagonists (spironolactone) for refractory edema and ascites; treat underlying left-sided disease; long-course IV antibiotics if endocarditis Daily weight monitoring; low-sodium diet; wound/skin care for edematous skin; IV drug use cessation resources; follow-up for underlying cause
Pulmonic stenosis Exertional symptoms (dyspnea, syncope); RV signs (parasternal heave, JVD); SpO2 (cyanosis risk in severe PS with patent foramen ovale); murmur character at left upper sternal border Activity restriction in symptomatic or severe PS; post-valvuloplasty monitoring (RV pressure gradient trending); telemetry for conduction abnormalities post-procedure Generally limited medical options; diuretics for RV failure; prostaglandins not applicable to isolated PS; post-valvuloplasty anticoagulation per protocol Mild PS: reassurance, follow-up schedule (annual echo), when to report increased symptoms; severe/post-procedure: activity restrictions, infective endocarditis prophylaxis if applicable

Valvular disease and heart failure

All significant valvular lesions – whether stenotic or regurgitant, left-sided or right-sided – eventually impair cardiac output and elevate filling pressures, producing heart failure. Understanding the direction of that failure is important for nursing priorities:

Left-sided valvular disease (mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation) primarily produces left heart failure: pulmonary venous hypertension, pulmonary edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Advanced left-sided disease transmits backward to cause pulmonary arterial hypertension and then right heart failure as well.

Right-sided valvular disease (tricuspid regurgitation, pulmonic stenosis) primarily produces right heart failure: elevated systemic venous pressure, JVD, peripheral edema, hepatomegaly, and ascites – with relatively spared pulmonary circulation.

This distinction helps nurses prioritize: a patient with severe mitral stenosis needs respiratory monitoring and supine position adjusted upward; a patient with severe tricuspid regurgitation needs abdominal assessment and meticulous fluid balance.

For comprehensive heart failure nursing, including assessment, diuretic therapy, hemodynamic targets, and patient education, see the heart failure nursing reference.

Infective endocarditis and valvular disease

Any valvular abnormality – whether congenital or acquired – creates turbulent blood flow that predisposes to bacterial seeding of the valve endothelium. Once established, endocarditis progressively destroys valve tissue, causing acute regurgitation (most commonly) or, less often, obstruction from bulky vegetations.

Key connections:

  • IV drug use is the leading risk factor for right-sided endocarditis (tricuspid valve) – Staphylococcus aureus, with septic pulmonary emboli
  • Dental procedures and invasive procedures are triggers for left-sided endocarditis in patients with pre-existing valve disease
  • Endocarditis prophylaxis is indicated for high-risk patients (prosthetic valves, prior endocarditis, certain congenital defects) undergoing dental procedures – 2g amoxicillin 30–60 minutes before the procedure

For Duke criteria, antibiotic regimens, and detailed nursing management, see the infective endocarditis nursing reference.

Cardiac rhythm monitoring in valvular disease

Valvular disease places patients at high risk for arrhythmias. Nurses must understand the rhythm risks associated with each valve disorder:

  • Mitral stenosis – LA enlargement is the substrate for AFib; AFib occurs in up to 40% of patients with significant MS and worsens symptoms acutely
  • Mitral regurgitation – chronic LA and LV dilation both predispose to AFib and ventricular arrhythmias
  • Aortic stenosis – LV hypertrophy creates an arrhythmogenic substrate; new AFib can precipitate acute decompensation; TAVR procedure carries risk of complete heart block and new left bundle branch block requiring temporary or permanent pacing
  • Tricuspid regurgitation – RA dilation predisposes to AFib and atrial flutter
  • Pulmonic stenosis – post-repair patients may develop right bundle branch block; severe PS with RV failure can cause atrial arrhythmias

Continuous telemetry is standard for hospitalized patients with significant valvular disease. See the EKG interpretation cheat sheet for rhythm recognition.

Pharmacology in valvular heart disease

Several medication categories are central to valvular disease management – and a few that are standard in other cardiac conditions carry specific risks in VHD:

  • Cardiovascular medications reference – see cardiovascular medications nursing for detailed drug class coverage including ACE inhibitors, beta-blockers, anticoagulants, and diuretics

Critical medication cautions:

MedicationSafe inUse caution/contraindicated in
Nitrates (nitroglycerin)Most cardiac conditionsAortic stenosis (risk of severe hypotension – preload-dependent valve)
Beta-blockersMitral stenosis (rate control), chronic MR, most conditionsAcute AR (slows HR, worsens diastolic regurgitation); acute decompensated AS
Vasodilators (ACE inhibitors, hydralazine)Chronic AR, chronic MRAortic stenosis (reduce preload/afterload in fixed obstruction – can cause hemodynamic collapse)
DigoxinRate control in MS with AFib; systolic HFHOCM (increases obstruction); use cautiously in most VHD settings
DiureticsMitral stenosis, TR, pulmonary congestionAortic stenosis (over-diuresis → preload collapse); HOCM

See the cardiovascular medications nursing reference for dosing, monitoring parameters, and full contraindication profiles.

NANDA-I nursing care plans

Care plan 1: decreased cardiac output

Nursing diagnosis: Decreased cardiac output Related to (R/T): Altered valve function – stenosis obstructing forward flow or regurgitation causing backward flow – resulting in impaired stroke volume and reduced systemic perfusion As evidenced by (AEB): Fatigue, dyspnea on exertion, reduced exercise tolerance, hypotension, tachycardia, cool extremities, decreased urine output, diminished peripheral pulses, S3 or S4 gallop, murmur on auscultation

InterventionRationale
Auscultate cardiac sounds at each shift assessment; document murmur timing (systolic vs. diastolic), location, radiation, quality, and any change from baseline.Murmur character changes – new onset, louder grade, or quality shift – may signal valve deterioration, acute regurgitation, or worsening stenosis requiring immediate escalation.
Monitor heart rate, blood pressure, pulse pressure, and SpO2 continuously; report MAP below 65 mmHg, SBP below 90 mmHg, or SpO2 below 94%.Falling MAP and narrowing pulse pressure reflect declining stroke volume; wide pulse pressure (>60 mmHg) indicates significant aortic regurgitation; prompt reporting enables timely intervention.
Assess peripheral perfusion hourly in acutely ill patients: capillary refill, skin temperature, pulses (radial, pedal), and mental status.Peripheral vasoconstriction, delayed capillary refill (>3 seconds), and altered sensorium are early signs of low-output state and cardiogenic compromise.
Position patient with head of bed at 30–45° unless hemodynamically unstable; use left lateral decubitus for auscultation of diastolic murmurs (mitral stenosis).Elevating the head reduces venous return and pulmonary congestion; left lateral decubitus increases sensitivity for low-pitched diastolic rumbles of mitral stenosis by shifting the heart toward the chest wall.
Administer prescribed diuretics (furosemide) and titrate to euvolemia; monitor urine output ≥0.5 mL/kg/hour and daily weights for trends.Reducing preload relieves pulmonary congestion in mitral stenosis and left-sided failure; however, excessive diuresis in aortic stenosis collapses preload and can precipitate hemodynamic compromise.
In aortic stenosis: avoid vasodilators (nitrates, ACE inhibitors, alpha-blockers) unless specifically ordered; hold nitroglycerin for AS-related angina and notify the provider.The stenotic aortic valve creates a fixed outflow obstruction; vasodilators reduce preload and afterload simultaneously, causing precipitous hypotension and syncope because LV output cannot increase to compensate.
Monitor CO/CI via PA catheter or non-invasive cardiac output monitoring if available; target CI >2.2 L/min/m² and PCWP 15–18 mmHg in decompensated patients.CI <2.2 L/min/m² defines cardiogenic compromise; elevated PCWP indicates pulmonary venous hypertension from left-sided valvular dysfunction; values guide diuresis and vasoactive therapy titration.
Obtain 12-lead ECG for any new or worsening symptoms; look for new AFib, conduction delays (PR prolongation, LBBB post-TAVR), and LVH voltage criteria.New AFib precipitates acute hemodynamic deterioration in mitral stenosis (loss of atrial kick, increased rate); post-TAVR complete heart block may require emergent pacing.
Administer oxygen to maintain SpO2 ≥94%; apply nasal cannula at 2–4 L/min initially, escalating to non-rebreather or NIV for pulmonary edema.Supplemental oxygen corrects hypoxemia from pulmonary venous congestion and reduces myocardial oxygen demand by improving arterial saturation.
Prepare patient for diagnostic or interventional procedures as indicated (echocardiogram, cardiac catheterization, TAVR, SAVR, balloon valvuloplasty); complete pre-procedure checklists, consent, and NPO protocols.Definitive management of severe valvular disease requires intervention; nursing preparation includes safety checks (anticoagulation status, allergies, access site assessment) that directly affect procedural safety.

Care plan 2: activity intolerance

Nursing diagnosis: Activity intolerance Related to (R/T): Imbalance between myocardial oxygen supply and demand caused by fixed valvular obstruction (stenosis) or volume overload (regurgitation), resulting in impaired cardiac reserve As evidenced by (AEB): Dyspnea on exertion, fatigue with minimal activity, NYHA Class II–IV functional limitation, exertional angina (aortic stenosis), exertional presyncope or syncope, oxygen desaturation with activity

InterventionRationale
Perform a baseline functional assessment using the NYHA classification: Class I (no symptoms), Class II (symptoms with moderate exertion), Class III (symptoms with minimal exertion), Class IV (symptoms at rest). Document class on admission and reassess with each clinical change.NYHA class is the standard tool for quantifying functional limitation in VHD, correlates with hemodynamic severity, guides intervention timing, and provides a reproducible metric for tracking deterioration or improvement.
Monitor heart rate, blood pressure, respiratory rate, and SpO2 before, during, and 3 minutes after any activity; stop activity and report if HR increases >20 bpm above resting, SBP drops >10 mmHg, SpO2 falls below 94%, or patient develops angina, presyncope, or diaphoresis.Exertional hypotension in aortic stenosis reflects inability to augment cardiac output across the fixed obstruction – a warning sign of imminent syncope; SpO2 drop indicates pulmonary congestion worsening with effort.
Implement a graded activity program in collaboration with cardiac rehabilitation or physical therapy: start with dangling at bedside, advance to standing and ambulation in the room, then corridor ambulation as tolerated.Progressive activity within hemodynamic limits prevents deconditioning without exceeding cardiac reserve; cardiac rehabilitation reduces hospitalizations and improves functional capacity in VHD patients.
Schedule activities to allow adequate rest periods; cluster nursing care to minimize unnecessary interruptions; prioritize highest-energy activities during peak energy periods (typically mid-morning).Clustering care reduces cumulative oxygen demand; planned rest prevents fatigue accumulation that would further limit tolerance for essential daily activities.
Educate the patient to use the Borg Rate of Perceived Exertion scale (RPE 11–13: “light to somewhat hard”); instruct to stop activity immediately with chest pain, lightheadedness, sudden dyspnea, or palpitations.Self-monitoring with RPE empowers patients to recognize their safe activity threshold; symptoms requiring immediate rest are warning signs of exertional hemodynamic compromise.
For patients awaiting valve intervention, establish activity restrictions appropriate to NYHA class and valve severity; document activity orders clearly and communicate to all team members.Uncontrolled exertion in severe aortic stenosis can precipitate exertional syncope or sudden cardiac death; clear written activity orders prevent conflicting instructions from different team members.
Arrange referral to cardiac rehabilitation following valve intervention (TAVR, SAVR, balloon valvuloplasty); educate patient on expected postoperative functional recovery timeline.Supervised cardiac rehabilitation after valve intervention significantly improves functional outcomes, exercise capacity, and quality of life compared to unsupervised recovery.
Assess for and treat contributing factors that worsen activity intolerance: anemia (reduces oxygen-carrying capacity), deconditioning, poorly controlled AFib (rate control), and fluid overload.Comorbidities independently limit activity tolerance; correcting anemia with target Hgb >10 g/dL, achieving heart rate control in AFib (<80 bpm at rest), and achieving euvolemia each independently improve functional capacity.

Care plan 3: risk for ineffective peripheral tissue perfusion

Nursing diagnosis: Risk for ineffective peripheral tissue perfusion Related to (R/T): Reduced cardiac output from valvular dysfunction; embolic risk from atrial fibrillation, left atrial thrombus (mitral stenosis), or prosthetic valve thrombosis; hypercoagulable state As evidenced by (AEB): [Risk diagnosis – no AEB required; presence of AFib, mechanical prosthetic valve, mitral stenosis with LA enlargement, or history of prior embolism]

InterventionRationale
Assess peripheral perfusion every 4–8 hours: bilateral pedal, radial, and posterior tibial pulses; capillary refill; skin color, temperature, and turgor; any new asymmetry or unilateral changes.Unilateral pulse loss or acute limb findings suggest peripheral arterial embolism from intracardiac thrombus; early detection enables urgent vascular intervention before irreversible ischemia.
Monitor neurological status at every nursing assessment: orientation, speech, facial symmetry, limb strength bilaterally; report any new focal deficit immediately.Systemic embolism most commonly affects the cerebral circulation; early stroke recognition activates time-sensitive treatment protocols – the window for thrombolysis or thrombectomy is narrow.
Administer anticoagulation as prescribed and monitor therapeutic levels: warfarin with target INR 2.5–3.5 for mechanical mitral valves, INR 2.0–3.0 for mechanical aortic valves; INR 2.0–3.0 for atrial fibrillation-related thromboembolism prevention; draw levels per protocol and report subtherapeutic or supratherapeutic values to the provider.Precise INR targets differ by valve position and type; the mitral position carries higher thrombogenic risk than the aortic position, requiring a higher INR target; values outside range increase either clot or bleeding risk.
In patients on warfarin, review all new medications for interactions; hold warfarin and notify provider before procedures; maintain a bridging anticoagulation plan per protocol for periprocedural management.Warfarin has extensive drug-drug interactions (amiodarone, antibiotics, NSAIDs, herbal supplements); abrupt discontinuation in high-risk mechanical valve patients carries significant thromboembolism risk requiring structured bridging.
For patients with mitral stenosis and AFib without anticoagulation, ensure fall precautions are in place while anticoagulation is being initiated; educate patient on bleeding risk signs (unusual bruising, blood in urine or stool, prolonged bleeding from cuts).Anticoagulation initiation increases bleeding risk; fall prevention reduces the risk of intracranial hemorrhage from anticoagulant-related trauma; patient awareness of bleeding signs enables prompt reporting.
Inspect lower extremities daily for signs of DVT: asymmetric calf swelling, warmth, tenderness, Homan’s sign (low sensitivity but still assessed); apply sequential compression devices (SCDs) for immobile patients not on anticoagulation.Valvular disease patients are at compounded DVT risk from immobility, low cardiac output, and venous stasis; SCDs provide mechanical prophylaxis when anticoagulation is contraindicated.
Ensure adequate hydration (unless fluid-restricted); avoid dehydration, which concentrates blood and increases viscosity, raising thrombotic risk in mechanically vulnerable patients.Dehydration increases blood viscosity and promotes stasis within cardiac chambers and slow-flow segments, compounding the intrinsic thrombogenic risk of dilated cardiac chambers and mechanical valves.
For post-TAVR patients, administer dual antiplatelet therapy (aspirin 75–100 mg + clopidogrel 75 mg) as prescribed; maintain for the prescribed duration (typically 3–6 months); then aspirin indefinitely.Transcatheter bioprosthetic valves require antiplatelet rather than anticoagulant therapy (absent AF); the dual antiplatelet period covers the leaflet endothelialization phase when thrombotic risk is highest.

Care plan 4: deficient knowledge – valve disease management

Nursing diagnosis: Deficient knowledge Related to (R/T): New or evolving diagnosis of valvular heart disease; unfamiliarity with anticoagulation management, endocarditis prophylaxis requirements, activity restrictions, symptom monitoring, and follow-up expectations As evidenced by (AEB): Patient or family verbalize unfamiliarity with condition or treatment; failure to identify symptoms requiring medical attention; incorrect medication administration; non-adherence with follow-up appointments; questioning the need for antibiotic prophylaxis

InterventionRationale
Assess the patient’s baseline knowledge, health literacy, and preferred learning style before initiating teaching; use teach-back to verify comprehension rather than asking yes/no questions.Identifying knowledge gaps prevents information overload; teach-back (patient explains information back in their own words) is the most validated method for confirming health literacy comprehension.
Teach the symptom triad of aortic stenosis and when to call 911: new exertional syncope, new angina, or new/worsening dyspnea on exertion are signs of severe AS requiring urgent evaluation – these symptoms mark a sharp decrease in prognosis without intervention.The AS symptom triad (syncope, angina, dyspnea) has prognostic survival correlations of 3, 5, and 1–2 years respectively; early symptom recognition by the patient enables timely referral for valve intervention.
Teach warfarin management for patients with mechanical valves or atrial fibrillation: take warfarin at the same time each day; never skip or double a dose; consistent vitamin K dietary intake (do not avoid leafy greens – keep intake consistent week to week); avoid NSAIDs; INR target and testing schedule; bleeding precautions.Erratic dietary vitamin K, missed doses, and NSAID co-administration are the most common causes of INR instability; consistent patient behavior reduces dose adjustment frequency and thromboembolism risk.
Educate patients with high-risk valve conditions (mechanical prosthetic valve, prior endocarditis, certain repaired congenital defects) on endocarditis prophylaxis: 2 g amoxicillin orally 30–60 minutes before dental procedures involving gum manipulation or mucosal incision; clindamycin 600 mg if penicillin-allergic; prophylaxis is NOT required for routine cleanings that do not involve gum manipulation.Current AHA 2007 guidelines restrict prophylaxis to highest-risk patients and highest-risk procedures; over-prescribing or patient self-medicating with wrong antibiotics provides no benefit and contributes to antimicrobial resistance.
Instruct patients on daily weight monitoring: weigh at the same time each morning after voiding, before eating; report a weight gain of more than 1 kg (2.2 lb) in 24 hours or 2 kg (4.4 lb) in 48 hours.Daily weights are the most sensitive early warning for fluid retention in heart failure and valvular disease; detecting early weight gain allows prompt diuretic adjustment before overt pulmonary edema develops.
Educate on activity guidelines specific to valve type and severity: no competitive sports or heavy isometric exertion with severe AS; swimming and low-resistance aerobic activity generally acceptable with mild-moderate disease; always check with the provider before starting a new exercise program.Isometric exertion and competitive sports increase LV outflow demand acutely; in fixed-obstruction AS, this demand cannot be met, raising the risk of exertional syncope and ventricular arrhythmia.
For patients with prosthetic valves, teach the difference between mechanical and bioprosthetic valves: mechanical valves require lifelong anticoagulation (warfarin); bioprosthetic valves have a limited lifespan (~10–20 years) and will likely need re-intervention; patients must inform all providers (including dentists) of their valve type.Patients often do not understand why anticoagulation must be lifelong or why follow-up echocardiography is mandatory; clear explanation of the valve lifespan differences reduces non-adherence and missed surveillance.
Provide written discharge instructions and a medication list; schedule follow-up echocardiogram and cardiology appointment before discharge; involve family or primary caregiver in all teaching sessions.Verbal-only discharge education is retained poorly; written materials plus caregiver involvement significantly improve adherence; pre-scheduled follow-up reduces the rate of lost-to-follow-up in a population requiring lifelong surveillance.

Nursing diagnosis: Anxiety Related to (R/T): Uncertain prognosis, potential requirement for open-heart surgery or transcatheter intervention, fear of anesthesia, hemodynamic monitoring, disruption of daily life, and concern about long-term outcomes As evidenced by (AEB): Verbalization of fear about the future, restlessness, diaphoresis, tachycardia, insomnia, increased questioning about prognosis, reluctance to ask questions, or withdrawal from family

InterventionRationale
Conduct an anxiety assessment using a validated scale (GAD-2 or VAS anxiety) at admission; document the patient’s specific fears (e.g., “I’m afraid of surgery” vs. “I don’t understand what’s happening to my heart”).Specific fear identification allows targeted intervention – a patient fearing surgery needs different support than one who fears loss of independence; undifferentiated “reassurance” without addressing the specific concern is ineffective.
Explain all monitoring equipment, alarms, procedures, and physical findings (e.g., what the murmur is and what it means) in plain language before they occur; narrate nursing assessments as you perform them.Environmental predictability reduces ambient anxiety; patients who understand their monitoring equipment and test results experience lower distress than those who hear alarms without context.
Provide structured information about the expected care pathway – hospitalization phases, diagnostic workup, consultation sequence, and likely timelines – using written or visual aids appropriate to health literacy.Uncertainty about what will happen next is a major driver of cardiac patient anxiety; a clear roadmap of likely next steps reduces anticipatory anxiety even when the ultimate outcome is unknown.
Facilitate a meeting between the patient, family, and the cardiologist or cardiac surgeon to discuss intervention options (TAVR, SAVR, balloon procedures), risks, benefits, and recovery expectations before consent is obtained.Patients who have had their questions answered by the procedural team before consent report significantly lower pre-procedure anxiety and better satisfaction with shared decision-making.
Teach and practice slow diaphragmatic breathing (4-second inhale, hold 2 seconds, 6-second exhale) as an immediately usable anxiety management technique; practice together at the bedside.Controlled slow breathing activates the parasympathetic nervous system, lowers heart rate, and reduces the physiological arousal component of anxiety – effects are reproducible within a single practice session.
Assess for clinically significant anxiety or depression using PHQ-2 screening; refer to social work, chaplaincy, or a clinical psychologist if the patient screens positive or identifies psychosocial support needs.Up to 40% of patients with significant valvular disease have clinically significant anxiety or depression; untreated psychological distress is independently associated with worse recovery, medication non-adherence, and reduced quality of life.
Involve the patient actively in decisions about their care where possible – positioning, timing of procedures, visitor policies, activity pacing; provide choice within safe limits.Perceived control is one of the strongest buffers against healthcare anxiety; even small decisions (choosing meal timing, choosing which arm for IV access) measurably reduce distress in hospitalized cardiac patients.
Reassure the patient that asking questions is encouraged; provide a written list of “questions to ask your cardiologist” tailored to their specific valve condition before provider rounds.Patients with cardiac diagnoses consistently report that having organized questions for the provider improves their sense of agency; prepared questions also improve the clinical information exchange during brief provider visits.

Frequently asked questions: valvular heart disease nursing

What is the priority nursing assessment for a patient with valvular heart disease?

The priority assessment is cardiovascular status: auscultation of heart sounds and murmur characteristics (timing, location, radiation, intensity), vital signs including pulse pressure, respiratory status (dyspnea, crackles, SpO2), and peripheral perfusion. In a patient with known aortic stenosis, syncope or new angina are red-flag findings requiring immediate escalation. In mitral stenosis, new AFib or worsening dyspnea should trigger urgent reassessment of hemodynamics and pulmonary status.

What are the most common nursing diagnoses for valvular heart disease?

The five core NANDA-I diagnoses are decreased cardiac output (related to altered valve function), activity intolerance (related to impaired cardiac reserve), risk for ineffective peripheral tissue perfusion (related to thromboembolic risk or low-output state), deficient knowledge (related to anticoagulation management, endocarditis prophylaxis, and symptom monitoring), and anxiety (related to uncertain prognosis and potential surgical intervention).

What is the difference between nursing management of aortic stenosis and mitral stenosis?

In aortic stenosis, the central nursing concern is maintaining adequate preload – vasodilators and nitrates are avoided because they can precipitate severe hypotension in a patient whose LV output is fixed by the stenotic obstruction. Rate is less critical. In mitral stenosis, rate control is the central pharmacologic priority: a fast heart rate shortens diastolic filling time across the narrowed valve and acutely worsens cardiac output. Both conditions share dyspnea and fatigue, but the hemodynamic mechanisms differ enough that medication management is nearly opposite.

How do nurses monitor for valve deterioration over time?

Interval assessment involves tracking symptoms using NYHA functional classification, documenting any new or changing murmur characteristics at each encounter, monitoring exercise tolerance and daily weight trends, reviewing serial echocardiography reports for changes in valve gradient and area, and watching for new arrhythmias (particularly AFib in mitral or aortic disease) on telemetry. Any new symptom from the aortic stenosis triad – angina, syncope, dyspnea on exertion – warrants urgent cardiology escalation regardless of when the last echo was performed.

What are the nursing considerations for anticoagulation in mechanical valve patients?

Mechanical valve patients require lifelong warfarin; target INR is 2.5–3.5 for mechanical mitral valves and 2.0–3.0 for mechanical aortic valves. Nursing responsibilities include monitoring INR results and reporting out-of-range values, assessing for bleeding (unusual bruising, blood in urine or stool, prolonged bleeding from cuts), reviewing all new medications for warfarin interactions (particularly amiodarone, azole antifungals, and antibiotics), maintaining consistent dietary vitamin K intake, and holding warfarin with a documented bridging plan for procedures. NOACs (apixaban, rivaroxaban) are contraindicated for mechanical valve patients – warfarin remains the only approved anticoagulant.

When should a nurse escalate a patient with valvular heart disease?

Escalation triggers include: new or worsening dyspnea with SpO2 below 94%, new or worsening chest pain especially in aortic stenosis patients (do not give nitrates without provider guidance), new-onset syncope or near-syncope, sudden change in murmur character or new murmur in a patient without prior documented murmur, new focal neurological signs (possible cerebral embolism), hemodynamic instability (MAP <65 mmHg, HR >120 bpm with symptoms), new irregular rhythm suggesting AFib, or acute pulmonary edema (especially in mitral stenosis or acute mitral/aortic regurgitation).

What is the nursing management after valve replacement surgery?

Post-operative priorities depend on approach. After surgical valve replacement (SAVR), nursing management includes mediastinal and pleural chest tube output monitoring, hemodynamic stabilization, ventilator weaning, sternal wound assessment, and early ambulation protocols. After TAVR, nursing focuses on access site assessment (femoral or radial), post-procedure telemetry for new LBBB or complete heart block (which may require permanent pacemaker), antiplatelet adherence (dual antiplatelet therapy for 3–6 months), and early discharge preparation since TAVR patients often go home within 24–48 hours. Both groups require education on the type of valve implanted, anticoagulation or antiplatelet requirements, activity restrictions, and when to seek urgent care.

What is endocarditis prophylaxis and which patients with valvular heart disease need it?

Per the 2007 AHA guidelines, endocarditis prophylaxis is now recommended only for the highest-risk patients undergoing the highest-risk procedures. Patients who require prophylaxis include those with mechanical prosthetic heart valves, bioprosthetic valves, a prior history of infective endocarditis, certain unrepaired or residual congenital heart defects, and cardiac transplant recipients who develop valvular disease. The prophylaxis-requiring procedures are those involving manipulation of gingival tissue or the periapical region of teeth, or perforation of the oral mucosa. The regimen is amoxicillin 2 g orally 30–60 minutes before the procedure; clindamycin 600 mg for penicillin-allergic patients. Routine dental cleanings without gum manipulation do not require prophylaxis. Nursing’s role is ensuring the patient’s valve history is documented and communicated to procedural teams.

NCLEX tips

  • Diastolic murmurs = aortic regurgitation or mitral stenosis. Systolic murmurs = aortic stenosis or mitral regurgitation. This is the most fundamental NCLEX differentiator. Memorize it: stenosis of the AV (a valve that opens in systole) causes a systolic murmur; regurgitation of the MV (a valve that should be closed in systole) causes a systolic murmur. Flip the reasoning for diastole.

  • Aortic stenosis classic triad: syncope, angina, dyspnea on exertion – appearing in that order as stenosis worsens. Survival after symptom onset: angina = 5 years, syncope = 3 years, dyspnea/HF = 1–2 years. These numbers appear on NCLEX.

  • The opening snap of mitral stenosis comes after S2, not before. The shorter the S2-to-opening snap interval, the more severe the stenosis (higher LA pressure = more forceful, earlier leaflet opening). A longer interval = milder stenosis.

  • NEVER give nitrates for angina in aortic stenosis without extreme caution. Nitroglycerine causes preload and afterload reduction. In AS, the LV depends on adequate filling to push blood through the stenotic valve. Nitrates can cause catastrophic hypotension. This is a classic NCLEX trap: the patient with AS has chest pain – what do you give? Call the provider before administering nitrates; it is not routine first-line treatment.

  • Papillary muscle rupture post-MI = acute mitral regurgitation – presents 2–7 days after MI with sudden onset pulmonary edema and a new holosystolic murmur. This is a surgical emergency. The nurse’s role: recognize the new murmur + hemodynamic deterioration and escalate immediately.

  • Corrigan’s pulse + wide pulse pressure = aortic regurgitation. Widened pulse pressure (systolic minus diastolic >60 mmHg) is the hemodynamic signature. The bounding, water-hammer pulse quality reflects the large stroke volume and rapid diastolic runoff. NCLEX will describe “bounding pulses” and a “wide pulse pressure” – the answer is aortic regurgitation.

  • Mitral stenosis + AFib = embolic stroke risk. LA enlargement from MS creates stasis in the LA appendage. AFib removes the atrial kick and further promotes stasis. The combination mandates anticoagulation. On NCLEX, a patient with MS who develops irregular rhythms and new neurological changes = stroke from LA thrombus embolization.

  • The tricuspid regurgitation murmur increases with inspiration (Carvallo’s sign) – right-sided murmurs increase with inspiration because inspiratory negative pressure increases venous return to the right heart, augmenting right-sided flow. Left-sided murmurs (MR, AS) are louder with expiration. Inspiration = right side; expiration = left side.

  • Pulmonic stenosis ejection click decreases with inspiration – this is opposite to the aortic ejection click (which is unaffected by respiration). The pulmonic ejection click is loudest in expiration and softer in inspiration; the NCLEX can test this as a distinguishing feature of pulmonic vs aortic valve origin of an ejection click.

  • IV drug use + right-sided valve disease = tricuspid endocarditis. The NCLEX question will describe a patient with IV drug use presenting with fever, septic pulmonary emboli (pleuritic chest pain, multiple pulmonary opacities on CXR), and a murmur at the left lower sternal border. The answer is tricuspid valve infective endocarditis from Staphylococcus aureus. See infective endocarditis nursing.

  • Aortic stenosis murmur radiates to the carotids; mitral regurgitation murmur radiates to the axilla. Both are heard best at different locations: AS at the right upper sternal border; MR at the apex. Radiation pattern is a key NCLEX exam differentiator – radiation to the neck = aortic origin; radiation to the axilla = mitral regurgitation.

  • TAVR post-procedure nursing: watch for conduction defects. The TAVR procedure places a prosthetic valve inside the native calcified valve. The pressure of deployment can injure the cardiac conduction system – new left bundle branch block and complete heart block (requiring permanent pacemaker) are recognized complications. Post-TAVR patients need continuous telemetry, and the nurse must recognize and report new PR prolongation, LBBB, or complete heart block. See EKG interpretation cheat sheet.